Endogenous peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-25 and is reviewed periodically as new material appears.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Practical handling notes centre on limiting exposure to water, oxygen, and repeated temperature cycling. Weighed powder is often equilibrated to room temperature before opening to avoid condensation on the solid. Working solutions are typically divided into single-use aliquots and frozen rather than stored refrigerated for long periods. Reported shelf lives vary widely between laboratories, and no single set of conditions is universally treated as a reference standard, which complicates direct comparison of published stability figures.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
== Clinical significance == Depending on genetic and nongenetic factors including alterations in gene expression, splice variations, post-translational modifications, and the chain-specific assembly of particular α-chains, different organs can be affected during their development and in the adult life span. Collagen IV has been the focus of extensive research ranging from biochemistry perspectives, to pathology, and genetic disorders. This is the only collagen type that is encoded by six different genes. The six α-chains of collagen IV can recognize each other with incredible specificity and will assemble into unique heterotrimers. After secretion into the extracellular membrane, these molecules will further interact to form higher molecular organizations. These, along with other proteins, will form unique basement membranes in tissue-specific manners. Through interactions with specific cellular receptors such as integrins, the basement membrane collagen IV networks not only provide structural support to the cells and tissues, but they also affect the biological rate during and after the development. New discoveries keep unraveling information about genetic mutations, biosynthesis, molecular assembly, and network formation of type IV collagen, and this increases the understanding of the critical role of this collagen in health and disease.
== Decay and capture products == A 135Xe atom that does not capture a neutron undergoes beta decay to 135Cs, one of the 7 long-lived fission products, while a 135Xe that does capture a neutron becomes almost-stable 136Xe. The probability of capturing a neutron before decay varies with the neutron flux, which itself depends on the kind of reactor, fuel enrichment and power level; and the 135Cs / 136Xe ratio switches its predominant branch very near usual reactor conditions. Estimates of the proportion of 135Xe during steady-state reactor operation that captures a neutron include 90%, 39%–91% and "essentially all". For instance, in a (somewhat high) neutron flux of 1014 n·cm−2·s−1, the xenon cross section of σ = 2.65×10−18 cm2 (2.65×106 barn) would lead to a capture probability of 2.65×10−4 s−1, which corresponds to a half-life of about one hour. Compared to the 9.14 hour half-life of 135Xe, this nearly ten-to-one ratio means that under such conditions, essentially all 135Xe would capture a neutron before decay. But if the neutron flux is lowered to one-tenth of this value, like in CANDU reactors, the ratio would be 50-50, and half the 135Xe would decay to 135Cs before neutron capture. 136Xe from neutron capture ends up as part of the eventual stable fission xenon which also includes 134Xe, 132Xe, and 131Xe produced by fission and beta decay rather than neutron capture. Nuclei of 133Xe, 137Xe, and 135Xe that have not captured a neutron all beta decay to isotopes of caesium.
==== United States investigations ==== GlaxoSmithKline was being investigated by the FDA and the US Congress regarding Avandia. Senators Democrat Max Baucus and Republican Charles Grassley filed a report urging GSK to withdraw Avandia in 2008 due to the side effects. The report noted the drug caused 500 avoidable heart attacks a month, and Glaxo officials sought to intimidate doctors who criticized the drug. It also said GSK continued to sell and promote the drug despite knowing the increased risk of heart attacks and stroke. The Senate Finance Committee, in a panel investigation, revealed emails from GSK company officials that suggest the company downplayed scientific findings about safety risks dating back to 2000. It was also alleged by the committee that the company initiated a "ghostwriting campaign", whereby GSK sought outside companies to write positive articles about Avandia to submit to medical journals. GSK defended itself by presenting data that its own tests found Avandia to be safe, although an FDA staff report showed the conclusions were flawed. On July 14, 2010, after two days of extensive deliberations, the FDA panel investigating Avandia came to a mixed vote. Twelve members of the panel voted to take the drug off the market, 17 recommended to leave it on but with a more revised warning label, and three voted to keep it on the market with the current warning label.
Fold Type I — aspartate aminotransferase family Fold Type II — tryptophan synthase family Fold Type III — alanine racemase family (TIM-barrel) Fold Type IV — D-amino acid aminotransferase family Fold Type V — glycogen phosphorylase family
On 7 September 1992, the Ciskei Defence Force fired into a crowd of ANC members (led by Ronnie Kasrils, Cyril Ramaphosa, and Chris Hani) who demanded the reincorporation of Ciskei into South Africa. 28 people were killed, and hundreds injured in the massacre outside the sports stadium in Bisho, the small capital of Ciskei.
Sources: en.wikipedia.org
=== Protein hydrogels === Hydrogels have had a wide-range of applications in biomedical sciences. One commonly used type of hydrogel starting material is elastin-like polypeptides. SpyTag/SpyCatcher chemistry has been used to produce tailored molecular networks ("networks of spies") within these hydrogels that enable the encapsulation of living mammalian cells such as fibroblasts. Subsequent modifications have enabled photo-responsive hydrogel formation, user-defined control over cell-material interactions, combined hyaluronan-elastin-like polypeptides, as well creating protein scaffolds for enzyme flow biocatalysis.
== Academic career == Shulman began his academic career at Harvard Medical School, serving as an instructor and then as an assistant professor of medicine from 1984 to 1987. In 1987, he joined the faculty at Yale University as an assistant professor of medicine. He was promoted to associate professor in 1989 and became a full professor in both internal medicine and cellular and molecular physiology in 1996. From 1987 to 1993, he concurrently served as a lecturer in Yale's Department of Molecular Biophysics and Biochemistry. In 2009, he was appointed the inaugural George R. Cowgill Professor of Physiological Chemistry at Yale University, a position he continues to hold. Shulman served as Associate Director of both the Yale Diabetes Endocrinology Research Center and the Yale Medical Scientist Training Program from 1992 to 2012. In 2012, he became Co-Director of the Yale Diabetes Research Center. He has served on the editorial boards of journals including the Journal of Clinical Investigation, Cell Metabolism, Science Translational Medicine, and Proceedings of the National Academy of Sciences. He was also an Investigator of the Howard Hughes Medical Institute for 21 years and is now an Investigator Emeritus.
=== Former members === Free Territory of Trieste The Free Territory of Trieste (Zone A) was a member of the OEEC until 1954, when it merged with Italy and ceased to exist as an independent territorial entity.
=== Biomaterials and nanotechnology === Mechler engaged in the design and characterization of biomaterials, nanostructures as well as in the development of novel nanotechnologies throughout his career. He used multimodal atomic force microscopy to map charge transfer properties of the conductive copolymer poly(ethyldioxythiophene)–poly(styrenesulfonic acid), showing that efficient charge injection occurs at lamellar edges and can be improved by controlling lamellar orientation. In a collaborative project, he also presented a method utilizing surface acoustic waves to produce monodispersed submicron poly-ε-caprolactone particles, demonstrating how acoustic forces and evaporative processes influence particle size and morphology. In a joint study, Mechler established that 14-helical N-acetyl β3-peptides self-assemble into nanofibers and that their morphology, such as nano-beams and dendritic structures, can be tuned by adjusting the solvent and inter-fibril interactions, enabling new bio- and nanomaterial applications. By using far-IR spectroscopy and DFT modeling, he confirmed the structure of self-assembled fibrous nano-materials from unnatural tripeptides, showing that far-IR spectroscopy can effectively characterize bioinspired materials where crystallographic methods fall short. He further showcased that using two binding motifs in supramolecular assemblies creates metallosupramolecular frameworks with controlled nanorod and two-dimensional structures, with copper ions forming polynuclear metal complexes.
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.